| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Liangfang Zhang | Q87985981 |
| P2093 | author name string | Pavimol Angsantikul | |
| Ronnie H Fang | |||
| P2860 | cites work | Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform | Q24596232 |
| Vaccination greatly reduces disease, disability, death and inequity worldwide | Q24648884 | ||
| Pathogenesis of methicillin-resistant Staphylococcus aureus infection | Q24657579 | ||
| Outer membrane vesicles as platform vaccine technology | Q26766539 | ||
| Live-Attenuated Bacterial Vectors: Tools for Vaccine and Therapeutic Agent Delivery | Q28084076 | ||
| Synthetic Nanoparticles for Vaccines and Immunotherapy | Q28085375 | ||
| Nanotechnology: intelligent design to treat complex disease | Q28246583 | ||
| CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database | Q28584458 | ||
| Immunological properties of engineered nanomaterials | Q29615634 | ||
| Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. | Q30406937 | ||
| A universal polysaccharide conjugated vaccine against O111 E. coli | Q33419199 | ||
| A self-assembling peptide acting as an immune adjuvant | Q33640064 | ||
| Recent progress in adjuvant discovery for peptide-based subunit vaccines | Q34033780 | ||
| PRINT: a novel platform toward shape and size specific nanoparticle theranostics | Q34149121 | ||
| Clearance of pathological antibodies using biomimetic nanoparticles | Q34218004 | ||
| Role of pore-forming toxins in bacterial infectious diseases | Q34346202 | ||
| Adjuvants for human vaccines--current status, problems and future prospects | Q34373525 | ||
| Nanomedicine scale-up technologies: feasibilities and challenges | Q34577443 | ||
| Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery | Q34700358 | ||
| On natural and artificial vaccinations | Q35034062 | ||
| A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei | Q35088366 | ||
| Vaccines, Vaccination, and Vaccinology | Q35115796 | ||
| Nanotechnology and medicine | Q35164817 | ||
| Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy | Q35304894 | ||
| Modulating antibacterial immunity via bacterial membrane-coated nanoparticles | Q35447934 | ||
| Reorienting our view of particle-based adjuvants for subunit vaccines | Q35709212 | ||
| Engineered nanoparticles mimicking cell membranes for toxin neutralization | Q35991625 | ||
| Synthesis of Nanogels via Cell Membrane-Templated Polymerization | Q36037531 | ||
| Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy | Q36269694 | ||
| Releasable layer-by-layer assembly of stabilized lipid nanocapsules on microneedles for enhanced transcutaneous vaccine delivery | Q36331113 | ||
| Effect of chemical and heat inactivation on the antigenicity and immunogenicity of Vibrio cholerae. | Q36334594 | ||
| Vaccine delivery using nanoparticles. | Q36712817 | ||
| A biomimetic nanosponge that absorbs pore-forming toxins | Q36828355 | ||
| Nanoparticle biointerfacing by platelet membrane cloaking | Q36912680 | ||
| Safe and Immunocompatible Nanocarriers Cloaked in RBC Membranes for Drug Delivery to Treat Solid Tumors | Q36926013 | ||
| Nanoparticle-Based Antivirulence Vaccine for the Management of Methicillin-Resistant Staphylococcus aureus Skin Infection | Q37016217 | ||
| Targeting vault nanoparticles to specific cell surface receptors | Q37094289 | ||
| A vault nanoparticle vaccine induces protective mucosal immunity | Q37165790 | ||
| Nanoparticle-detained toxins for safe and effective vaccination | Q37426321 | ||
| Existing antibacterial vaccines | Q37428005 | ||
| Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future | Q37514748 | ||
| Pregnancy Vaccination with Gold Glyco-Nanoparticles Carrying Listeria monocytogenes Peptides Protects against Listeriosis and Brain- and Cutaneous-Associated Morbidities. | Q37577596 | ||
| Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles | Q37638568 | ||
| Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery | Q37701353 | ||
| Virus-like particles in vaccine development. | Q37798008 | ||
| Dendrimer-conjugated peptide vaccine enhances clearance of Chlamydia trachomatis genital infection | Q37834084 | ||
| Modulating immunity as a therapy for bacterial infections | Q37994068 | ||
| Erythrocyte-inspired delivery systems | Q38062897 | ||
| Challenges in the research and development of new human vaccines. | Q38096300 | ||
| Nanoparticle vaccines | Q38167942 | ||
| Oral delivery of nanoparticle-based vaccines. | Q38243119 | ||
| Nanoparticles as synthetic vaccines | Q38415876 | ||
| Streptococcal toxins: role in pathogenesis and disease | Q38598360 | ||
| Nanoparticle-Based Modulation of the Immune System | Q38825938 | ||
| Macrophage Cell Membrane Camouflaged Mesoporous Silica Nanocapsules for In Vivo Cancer Therapy. | Q38876987 | ||
| Core-shell supramolecular gelatin nanoparticles for adaptive and "on-demand" antibiotic delivery | Q39005991 | ||
| Intranasal delivery of nanoparticle-based vaccines. | Q39113247 | ||
| A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile. | Q39158452 | ||
| Receptor-specific delivery of protein antigen to dendritic cells by a nanoemulsion formed using top-down non-covalent click self-assembly | Q39162620 | ||
| Cell membrane-derived nanomaterials for biomedical applications | Q39178313 | ||
| Nanoparticles for immune system targeting. | Q39228204 | ||
| Bioengineering bacterial outer membrane vesicles as vaccine platform | Q39316489 | ||
| A transcutaneous vaccination system using a hydrogel patch for viral and bacterial infection. | Q39951061 | ||
| A Red Blood Cell Membrane-Camouflaged Nanoparticle Counteracts Streptolysin O-Mediated Virulence Phenotypes of Invasive Group A Streptococcus | Q40109133 | ||
| In Situ Capture of Bacterial Toxins for Antivirulence Vaccination | Q40155457 | ||
| Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses | Q40278311 | ||
| Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection. | Q40443989 | ||
| A novel chimeric flagellum fused with the multi-epitope vaccine CTB-UE prevents Helicobacter pylori-induced gastric cancer in a BALB/c mouse model. | Q41170807 | ||
| Carrier-induced epitopic suppression, a major issue for future synthetic vaccines | Q41375108 | ||
| Hollow microneedle-mediated intradermal delivery of model vaccine antigen-loaded PLGA nanoparticles elicits protective T cell-mediated immunity to an intracellular bacterium. | Q41997458 | ||
| Vaccination of calves with leukotoxic culture supernatant from Pasteurella haemolytica | Q42574255 | ||
| Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. | Q43012213 | ||
| Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice | Q43623067 | ||
| Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: low-burst release is crucial for efficient CD8(+) T cell activation | Q44300085 | ||
| Identification of formaldehyde-induced modifications in proteins: reactions with model peptides | Q44669066 | ||
| An improved method for development of toxoid vaccines and antitoxins. | Q46525857 | ||
| Intestinal patch systems for oral drug delivery | Q46738812 | ||
| Intradermal vaccination with hollow microneedles: A comparative study of various protein antigen and adjuvant encapsulated nanoparticles | Q46817527 | ||
| Development and characterization of a new carrier for vaccine delivery based on calcium-alginate nanoparticles: Safe immunoprotective approach against scorpion envenoming | Q46988098 | ||
| Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype | Q47097020 | ||
| Adjuvant-Loaded Spiky Gold Nanoparticles for Activation of Innate Immune Cells. | Q47226216 | ||
| Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose | Q47301856 | ||
| The perpetual challenge of infectious diseases | Q48489280 | ||
| Nanoparticles disguised as red blood cells to evade the immune system. | Q50517187 | ||
| Immunoadjuvant potential of cross-linked dextran microspheres mixed with chitosan nanospheres encapsulated with tetanus toxoid. | Q51024113 | ||
| Nano-sized Soluplus® polymeric micelles enhance the induction of tetanus toxin neutralising antibody response following transcutaneous immunisation with tetanus toxoid. | Q51091693 | ||
| Conjugate vaccines. | Q55033615 | ||
| Biomimetic strategies for targeted nanoparticle delivery. | Q55209384 | ||
| Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae | Q64130946 | ||
| "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells | Q80212165 | ||
| Exploiting lymphatic transport and complement activation in nanoparticle vaccines | Q81305052 | ||
| Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity | Q82267419 | ||
| [Experiences with cement leakage after balloon kyphoplasty] | Q85266480 | ||
| Nanovaccinology: the next generation of vaccines meets 21st century materials science and engineering | Q87446725 | ||
| P433 | issue | 3 | |
| P921 | main subject | nanoparticle | Q61231 |
| P304 | page(s) | 604-612 | |
| P577 | publication date | 2017-12-27 | |
| P1433 | published in | Bioconjugate Chemistry | Q2343023 |
| P1476 | title | Toxoid Vaccination against Bacterial Infection Using Cell Membrane-Coated Nanoparticles | |
| P478 | volume | 29 |
| Q89622549 | Biomimetic Nanoparticles Camouflaged in Cancer Cell Membranes and Their Applications in Cancer Theranostics |
| Q90055871 | Biomimetic nanoparticle technology for cardiovascular disease detection and treatment |
| Q99550889 | CD4+ T Cell-Mimicking Nanoparticles Broadly Neutralize HIV-1 and Suppress Viral Replication through Autophagy |
| Q58583152 | Engineering biological interactions on the nanoscale |
Search more.